- Home
- SPRO vs DTF Comparison
SPRO vs DTF Comparison
Compare SPRO & DTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- DTF
- Stock Information
- Founded
- SPRO 2013
- DTF 1991
- Country
- SPRO United States
- DTF United States
- Employees
- SPRO N/A
- DTF N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- DTF Investment Managers
- Sector
- SPRO Health Care
- DTF Finance
- Exchange
- SPRO Nasdaq
- DTF Nasdaq
- Market Cap
- SPRO 63.0M
- DTF 79.4M
- IPO Year
- SPRO 2017
- DTF N/A
- Fundamental
- Price
- SPRO $0.97
- DTF $11.24
- Analyst Decision
- SPRO Buy
- DTF
- Analyst Count
- SPRO 4
- DTF 0
- Target Price
- SPRO $5.00
- DTF N/A
- AVG Volume (30 Days)
- SPRO 247.7K
- DTF 21.1K
- Earning Date
- SPRO 11-14-2024
- DTF 01-01-0001
- Dividend Yield
- SPRO N/A
- DTF 3.64%
- EPS Growth
- SPRO N/A
- DTF N/A
- EPS
- SPRO 0.06
- DTF 0.44
- Revenue
- SPRO $106,455,000.00
- DTF N/A
- Revenue This Year
- SPRO N/A
- DTF N/A
- Revenue Next Year
- SPRO N/A
- DTF N/A
- P/E Ratio
- SPRO $15.29
- DTF $24.34
- Revenue Growth
- SPRO 37.01
- DTF N/A
- 52 Week Low
- SPRO $0.92
- DTF $10.29
- 52 Week High
- SPRO $1.89
- DTF $11.19
- Technical
- Relative Strength Index (RSI)
- SPRO 39.40
- DTF 53.47
- Support Level
- SPRO $0.92
- DTF $11.13
- Resistance Level
- SPRO $1.13
- DTF $11.30
- Average True Range (ATR)
- SPRO 0.06
- DTF 0.07
- MACD
- SPRO 0.00
- DTF 0.01
- Stochastic Oscillator
- SPRO 26.16
- DTF 87.28
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About DTF DTF Tax-Free Income 2028 Term Fund Inc.
DTF Tax-Free Income 2028 Term Fund Inc is a diversified closed-end management investment company. The Fund's investment objective is current income exempt from regular federal income tax consistent with the preservation of capital. It seeks to achieve its investment objective by investing primarily in a diversified portfolio of investment-grade tax-exempt obligations.